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Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease characterized by autoantibodies to type
VII (anchoring ﬁbril) collagen. Therefore, it is a prototypic autoimmune disease deﬁned by a well-known autoan-
tigen and autoantibody. In this study, we injected hairless immune competent mice with puriﬁed immunoglobulin G
(IgG) fraction of serum from rabbits immunized with the non-collagenous amino-terminal domain (NC1) of human
type VII collagen, the domain known to contain immunodominant epitopes. As a control, identical mice were
injected with the IgG fraction of serum from non-immunized rabbits. Mice injected with immune IgG developed
subepidermal skin blisters and erosions, IgG deposits at the epidermal–dermal junction of their skin, and circu-
lating anti-NC1 antibodies in their serum-all features reminiscent of patients with EBA. Similar concentrations of
control IgG puriﬁed from normal rabbits did not induce disease in the mice. These ﬁndings strongly suggest that
autoantibodies that recognize human type VII collagen in EBA are pathogenic. This murine model, with features
similar to the clinical, histological, and immunological features of EBA, will be useful for the ﬁne dissection of
immunopathogenic mechanisms in EBA and for the development of new therapeutic interventions.
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Epidermolysis bullosa acquisita (EBA) is an incurable auto-
immune blistering disease of the skin characterized by skin
fragility, blisters in trauma-prone sites, and scarring with
milia formation and nail dystrophy (Roenigk et al, 1971).
EBA is a prototypic autoimmune disease in which EBA pa-
tients have autoimmune immunoglobulin G (IgG) antibodies
in their blood and skin that are directed against a specific
structure in the skin called anchoring fibrils (Woodley et al,
1984, 1986, 1988). These structures are responsible for
holding together the two main layers of skin: the epidermis
and dermis (Briggaman and Wheeler, 1975). Anchoring fi-
brils are located within the basement membrane zone
(BMZ) between the epidermis and dermis. They are com-
posed of type VII collagen (Sakai et al, 1986; Keene et al,
1987; Burgeson, 1993). EBA autoantibodies bind to type VII
collagen within anchoring fibrils and this binding is associ-
ated with a diminution of normal anchoring fibrils in
the patient’s skin and subsequent epidermal–dermal
disadherance.
Type VII collagen is composed of three identical a chains
(Sakai et al, 1986; Keene et al, 1987; Burgeson, 1993). Each
a chain consists of a central collagenous domain flanked by
a 145 kDa non-collagenous amino-terminal domain (NC1)
and a 30 kDa carboxyl-terminal domain (Lunstrum et al,
1986, 1987). The primary binding site within the type VII
collagen molecule for EBA autoantibodies is the NC1 do-
main (Gammon et al, 1993; Lapiere et al, 1993; Jones et al,
1995).
The ‘‘Koch’s postulate’’ of autoimmune diseases shows
that the disease can be duplicated in an animal by injecting
into the animal an antibody specifically directed against the
autoantigen self-protein (in this case type VII collagen—so
called ‘‘passive transfer’’ of the disease) (Witebsky, 1966;
Rose and Bona, 1993). The duplication of the disease in
the animal proves that the antibody is ‘‘pathogenic’’ and
responsible for the disease phenotype. This has been
accomplished in the autoimmune diseases pemphigus
vulgaris, pemphigus foliaceus, and bullous pemphigoid
(Roscoe et al, 1985; Anhalt et al, 1993; Liu et al, 1993).
Several independent lines of evidence derived from clin-
ical, histologic, and immunologic studies have implicated
autoimmunity element in the pathogenesis of EBA. Con-
sistent induction of blisters in an animal by the passive
transfer of EBA IgG autoantibodies into the animal, howev-
er, has not been achieved, despite numerous attempts
(Shigemoto et al, 1988; Chen et al, 1992; Borradori et al,
1995). In earlier studies, when IgG autoantibodies were
injected into neonatal mice, they bound to the animal’s an-
choring fibrils, fixed complement, and generated an inflam-
matory infiltrate at the dermal–epidermal junction (DEJ), but
Abbreviations: BMZ, basement membrane zone; DEJ, dermal ep-
idermal junction; DIF, direct immunofluorescence; EBA, epidermo-
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immunofluorescence; NC1, 145 kDa non-collagenous domain of
type VII collagen
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
958
no dermal–epidermal separation was observed (Shigemoto
et al, 1988; Borradori et al, 1995). Likewise, Chen et al
(1992) also injected EBA serum and whole human blood into
SCID mice transplanted with human skin grafts but failed to
induce blisters in either murine or grafted human skin. Nev-
ertheless, the EBA serum IgG infused into the animal bound
to the BMZ of both the murine skin and the transplanted
human skin (Chen et al, 1992).
In this study, we raised a high titer antibody to recom-
binant human type VII collagen, specifically, the highly an-
tigenic NC1 domain (Chen et al, 1997). The resulting rabbit
antibody recognized both human and mouse type VII col-
lagen. We purified IgG fractions of the rabbit immune serum
and injected them intradermally into immunocompetent,
hairless mice. We found that passively transferring anti-NC1
antibodies into mice consistently induced a subepidermal
blistering disease resembling the clinical, histological, and
immunological features of human EBA.
Results
Preparation and puriﬁcation of recombinant human
NC1 We have previously expressed large quantities of the
recombinant NC1 domain of human type VII collagen in
human epithelial 293 cells (Chen et al, 1997). As shown in
Fig 1A, the 293 cells cannot constitutively synthesize and
secrete human type VII collagen (panel a, lane 1). After the
cells were transfected with the pRC/CMV vector containing
human cDNA for the NC1 domain of type VII collagen, the
cells synthesized and secreted the 145 kDa NC1 domain of
type VII collagen (lane 2). We purified the recombinant hu-
man NC1 protein from conditioned media to homogeneity
by column chromatography as previously described (panel
b) (Chen et al, 1997). The recombinant NC1 was then used
to immunize rabbits to produce polyclonal anti-NC1 anti-
bodies.
The IgG fraction of immune serum is specific for
NC1 We purified IgG from immunized rabbit sera. The an-
tigenic specificity of the immune IgG was characterized by
immunoblot analysis as shown in Fig 1B. The anti-NC1 IgG
only labeled the 145 kDa NC1 (lane 1) and did not label
other matrix proteins including type I collagen, type IV
collagen, fibronectin, laminin-1, and laminin-5 (Fig 1B,
lanes 2–6).
By indirect immunofluorescence (IIF) against human and
murine skin (Fig 1C), the purified IgG fraction from the rabbit
anti-NC1 sera strongly labeled the BMZ of both human and
mouse skin, whereas the IgG fraction from control rabbit
sera did not. IIF testing against salt-split human skin subst-
rate showed that the antibody labeled the dermal side,
consistent with labeling type VII (anchoring fibril) collagen
(Gammon et al, 1984, 1990). Serial dilutions of the IgG
fraction showed that the IgG contained anti-type VII colla-
gen antibodies against human and murine skin at titers over
1:100,000 and against salt-split human skin at greater than
1:200,000. Further, the IIF staining of human skin substrate
could be completely blocked by pre-absorption of the IgG
fraction with NC1-affinity column (panel D) but not by pre-
absorption with type IV collagen, fibronectin, and laminin-1
(data not shown).
Figure1
Production and characterization of purified rabbit anti-NC1 (145
kDa non-collagenous domain of type VII collagen) antibodies. (A)
Expression and purification of recombinant NC1 domain of human type
VII collagen from stably transfected 293 cells. (a) Conditioned media
from parental 293 cells (lane 1) and 293 cells stably transfected with an
expression vector coding for human NC1 (lane 2) were concentrated
and subjected to 6% SDS-PAGE followed by immunoblot analysis us-
ing a monoclonal antibody to NC1. The positions of the 145 kDa NC1
and molecular weight markers are indicated. (b) Six percent SDS-PAGE
and Coomassie blue staining of purified 145 kDa NC1. (B) Specificity of
rabbit anti-NC1 antibody for NC1. Purified recombinant NC1 as well as
other extracellular matrix components (400 ng per well) were separated
on 6% SDS-PAGE and transferred to nitrocellulose membranes before
incubation with rabbit anti-NC1 antibody at a dilution of 1:5000 and
horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (IgG)
(1:5000) followed by ECL detection. Lanes 1–6 are NC1, type I collagen,
type IV collagen, fibronectin, laminin-1, and laminin-5, respectively. The
location of the 145 kDa of recombinant NC1 and molecular weight
markers are indicated. (C) Immunolabeling of mouse and human skin
with purified rabbit anti-NC1 IgG. Immunofluorescence staining was
performed on human skin (panels A and D), mouse skin (panel B), and
salt-split human skin (panel C). The tissue was labeled with a purified
rabbit anti-NC1 antibody (panels A–C) and a flowthrough IgG fraction
from an NC1-affinity column (panel D) at a dilution of 1:5000 and a
fluorescein isothiocyanate-conjugated goat-anti rabbit IgG. Note that
the rabbit anti-NC1 antibody strongly labeled the basement membrane
zone (BMZ) of both mouse and human skin and the dermal floor of
salt-split human skin. In contrast, IgG depletion of reactivity to the
NC1 domain (flowthrough fraction) did not label the BMZ. d, dermis;
e, epidermis.
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IgG fractions from immunized rabbits induced skin fra-
gility, blisters, and erosions in mice SKH1 mice were
given daily intradermal injections of purified IgG fractions
prepared from the rabbit anti-NC1 antisera and control rab-
bit sera at doses from 0.1 to 1 mg per g body weight. As
shown in Fig 2, animals injected with the rabbit anti-NC1
IgG (n¼ 15) showed numerous erosions and crusts forming
from ruptured blisters as early as 4 d after the initial injection
at the injection site (panel A). With time, additional erosions
were observed, particularly on the ears at 8 d (panel B), hips
at 8 d (panel C), and paws at 24 d (panel D)—trauma-prone
sites where the animals scratch themselves. All of the 15
mice developed blisters and then erosions at the injection
site, and most, but not all mice, developed bullae and ero-
sions on the ears, hips, and paws. Nail loss was also ob-
served in 80% of injected mice (panel D). Mice continued
to develop new, increasingly severe, widespread erosions
even 1 mo after the initial series of 10 antibody injections
(panel E). We observed cutaneous lesions induced by the
rabbit anti-NC1 in all the injected mice (n¼ 15). In contrast,
no blisters or erosions developed in the mice injected with
rabbit control IgG (n¼5). We did not formally measure the
percentage involvement of the animals’ body surface area
with bullae and erosions and correlate this with the doses of
immune IgG given. Nevertheless, from the photographic
documentation of the mice, it is our overall impression that a
greater percentage of the total body surface area was in-
volved with erosions and blisters when the mice were given
higher (41 mg per g body weight) doses of rabbit anti-NCI
IgG. In fact, animals given doses less than 0.2 mg per g
body weight of immune IgG did not develop any skin le-
sions. Similarly, nail loss only occurred in mice given higher
IgG doses (X1 mg per g body weight—12 of 12 mice).
Histological and immunological examination of mice in-
jected with immune IgG Histological examination of
mouse skin injected intradermally with rabbit anti-NC1 IgG
demonstrated a full sub-epidermal blister with a clean sep-
aration between the epidermis and dermis (Fig 3A). There
was also a scattered dermal inflammatory infiltrate. In con-
trast, mice injected with similar concentrations of rabbit
control IgG had no skin pathology (Fig 3B). Direct immuno-
fluorescence (DIF) of perilesional and lesional skin of all
mice injected with rabbit anti-NC1 IgG showed strong dep-
osition of tissue-bound, rabbit, anti-NC1 IgG at the DEJ
between the epidermis and dermis of the mouse skin (Fig 4).
Also, in many mice, murine complement was detected at
the DEJ (Fig 4). Within the dermal inflammatory infiltrate,
neutrophils could be detected in small numbers (Fig 4).
There were no IgG or C3 deposits observed at the BMZ of
mice injected with rabbit control IgG. Further, neutrophils
were not detected in the skin of mice injected with rabbit
control IgG.
Figure 2
Cutaneous lesions induced in SKH1
mice by injection of rabbit anti-NC1
(145 kDa non-collagenous domain of
type VII collagen) immunoglobulin G
(IgG). SKH1 mice were injected intrad-
ermally with rabbit anti-NC1 IgG at 1 mg
per g body weight once every day for 6
consecutive days (panels A–D) or 10 con-
secutive days (panel E). Four days after
the injections were started (4  ), animals
developed numerous blisters, erosions,
and crusts forming from ruptured blisters
at the site of injection (A). These lesions
were observed on the animals’ ears (B)
and legs (C) at 8 d and paws (D) at 24 d
after initial injections (6  ). Nail loss was
also observed in some mice (D). Mice
continued to develop new, increasingly
severe, and widespread erosions even 1
mo (E) after the initial series of antibody
injections (10  ).
Figure3
Histological examination of lesional skin of SKH mice injected with
rabbit anti-NC1 (145 kDa non-collagenous domain of type VII col-
lagen) immunoglobulin G (IgG). (A) Hematoxylin and eosin staining of
lesional murine skin revealed separation of the epidermis (e) from the
dermis (d). This histologic finding is similar to that seen in lesional skin
of epidermolysis bullosa acquisita patients. No epidermal–dermal sep-
aration was seen in mice receiving equivalent amounts of rabbit control
IgG (B).
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Evaluation of sera from mice injected with rabbit
IgG Mice injected with rabbit anti-NC1 IgG had high titers
of circulating antibody (1:20,000–1:50,000) when assayed
by IIF against either normal or salt-split human skin. As
shown in Fig 5, serum from the diseased mice had rabbit
antibodies that bound to the DEJ of normal human skin
(panel A) and the dermal side of the salt-split human skin
(panel B), reminiscent of EBA patient sera. In contrast, se-
rum from mice injected with control IgG showed no binding
to the DEJ of human skin (panel C) even at dilutions of 1:10.
Discussion
In this study, we have shown that the sub-epidermal, au-
toimmune bullous disease, EBA, can be passively trans-
ferred into hairless, immune competent mice using rabbit
anti-NC1 IgG. We have shown previously that the NC1 do-
main of type VII collagen is a highly antigenic part of the
type VII collagen a chain and that the sera of most patients
with EBA contain IgG autoantibodies against NC1 (Lapiere
et al, 1993). The mice injected with anti-NC1 IgG from im-
munized rabbits developed sub-epidermal blisters and ero-
sions, reminiscent of the skin lesions seen in EBA patients.
Like many EBA patients, the mice often had loss of nails on
their paws. Also, like EBA patients, these mice exhibited
IgG deposits at the DEJ by DIF, one of the critical diagnostic
tests for human EBA. Like many EBA patients, the mice also
had anti-NC1 IgG antibodies circulating in their blood as
demonstrated by salt-split IIF. Taken together, the mice in-
jected with immune IgG exhibited clinical, histological, and
immunological features akin to patients with EBA.
Several independent lines of evidence derived from clin-
ical, histological, and immunological studies have implicat-
ed autoimmunity in the pathogenesis of EBA. Evidence for
the pathogenic role of EBA auto-antibodies also comes
from the observation that when patients with systematic
lupus erythematosus (SLE) develop autoantibodies to the
EBA antigen, they develop skin blisters and fall into a subset
called ‘‘bullous SLE’’ (Gammon et al, 1985). Patients with
SLE have an enhanced immune system and frequently
make autoantibodies to a variety of tissues. Normally, SLE
patients do not have skin fragility or blisters. But when SLE
patients serendipitously make autoantibodies to type VII
collagen, a widespread blistering eruption of the skin en-
sues. This ‘‘experiment of nature’’ suggests that EBA
autoantibodies are pathogenic and capable of inducing
disadherence between the epidermis and dermis.
Figure 4
Immunofluorescence analysis of SKH1
mice skin injected with rabbit anti-NC1
(145 kDa non-collagenous domain of
type VII collagen) immunoglobulin G
(IgG). Cryosections of perilesional and
lesional skin were labeled with fluorescein
isothiocyanate (FITC) goat anti-rabbit
IgG (a-R IgG), FITC-goat anti-mouse C3
(a-C3), and FITC-goat anti-mouse ne-
utrophils (a-Neu), respectively. Note that
the linear deposits of rabbit IgG and
murine C3 were found at the basement
membrane zone of perilesional and lesio-
nal mouse skin injected with rabbit anti-
NC1 IgG. Please also note the scattered
neutrophilis in the dermis. In contrast, in
mice receiving equivalent amounts of
purified rabbit control IgG (NRS), no de-
posits of rabbit IgG or murine C3 were
detected.
Figure 5
Immunolabeling of human skin with serum
from mice injected with rabbit anti-NC1 (145
kDa non-collagenous domain of type VII col-
lagen) immunoglobulin G (IgG). Sections of
normal human skin (A, C) and salt-split human
skin (B) were stained with mouse serum obtained
from mice injected with either rabbit anti-NC1
IgG (A, B) or control IgG (C) at a dilution of
1:2000. Note that circulating antibodies labeling
the basement membrane zone of human skin
and the dermal floor of salt-split human skin were found in the serum samples from mice injected with anti-NC1 IgG but not those injected with
control IgG.
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Our laboratory and others previously have attempted to
transfer EBA passively into mice using concentrated IgG
serum fractions and even whole blood from EBA patients
without success (Shigemoto et al, 1988; Chen et al, 1992;
Borradori et al, 1995). When IgG autoantibodies were
injected into neonatal mice, they bound to the animal’s
anchoring fibrils, fixed complement, and generated an
inflammatory infiltrate in the dermis, but no dermal–epider-
mal separation occurred.
With this novel EBA animal model being developed, sev-
eral possibilities could explain previous failures. First, in the
study by Borradori et al (1995), the investigators used neo-
natal mice for IgG passive transfer with only two injections
and a limited incubation time. The turnover of anchoring
fibrils is thought to be low (Burgeson, 1993). Existing res-
ident anchoring fibrils in the animals may have continued to
function despite the presence of EBA autoantibodies. It is
possible that multiple injections of EBA autoantibodies with
a longer time period may be needed to reproduce the man-
ifestations of EBA in an animal model. In this study, we
injected adult mice every day for up to 10 d.
Another potential factor may be the amount of anti-type
VII collagen antibody injected. In the previous studies, we
injected serum IgG fractions from EBA patients known to
have IgG autoantibodies to type VII collagen. Most EBA
patients have low titers of anti-type VII collagen antibodies
and much lower levels of NC1-specific IgG in their serum.
The amount of actual anti-type VII collagen antibodies in the
injected serum IgG fractions was likely extremely low. In the
study by Shigemoto et al (1988), EBA passive transfer was
attempted in adult mice for 3 consecutive days, but the
amount of IgG fraction injected was very low, only 0.13 mg
per g body weight. In this study, we raised rabbit antibodies
to the NC1 domain of type VII collagen. The titers in the IgG
fraction purified from the immunized animals were extreme-
ly high (41:100,000 against human and mouse skin sec-
tions by IIF and over 1:200,000 on human salt-split skin
substrate). Moreover, since the pathogenic epitopes on type
VII collagen are concentrated on the NC1 domain, we likely
created anti-type VII collagen antibodies directed against
the pathogenic epitopes. In addition, we administered mul-
tiple injections using IgG fraction at doses of 0.3–1.0 mg per
g body weight.
The NC1 domain of type VII collagen constitutes the
major immunodominant epitopes that are targeted by the
majority of EBA sera (Gammon et al, 1993; Lapiere et al,
1993; Jones et al, 1995). The fact that the IIF staining of
human skin substrate could be completely abolished by
pre-absorption of the anti-NC1 rabbit IgG fraction with NC1,
but not with type IV collagen, fibronectin, and laminin-1,
demonstrates the specificity of the anti-NC1 antibodies that
bind to the BMZ of mouse and human skin.
EBA patients often develop blisters and erosions in oral
mucosa. In these studies, we did not examine formally
whether the experimental mice had significant involve-
ment of the oral mucosa. The immune IgG-injected mice,
however, did not exhibit significant weight loss even
though they had many months of active skin lesions. This
suggests that the animals did not have significant oral
mucosal involvement that inhibited their ability to eat and
drink.
Anchoring fibrils are reduced in the skin of EBA patients,
but the underlying mechanism leading to this reduction is
unknown (Nieboer et al, 1980; Yaoita et al, 1981). Because
EBA often occurs with minimal clinical or histological in-
flammation, it has been hypothesized that defective epi-
dermal–dermal adherence in EBA involves autoantibodies
targeting functional epitopes within the type VII collagen
molecule. This could perturb critical direct interactions be-
tween type VII collagen and other extracellular components
within the DEJ such as type IV collagen, laminin-5, and
fibronectin (Lapiere et al, 1994; Chen et al, 1997; Chen et al,
1999). We and others have shown that specific domains
within the NC1 domain of the type VII collagen a chain have
affinity for laminin-5, type IV collagen, and fibronectin.
These interactions may be necessary for keeping the DEJ
intact (Lapiere et al, 1994; Chen et al, 1997; Chen et al,
1999). By this mechanism, it is possible to envision how a
patient could have skin fragility and poor adherence be-
tween the epidermis and dermis in association with a few
normal anchoring fibrils and also have minimal inflammation
in the lesions.
Classical EBA is associated with skin fragility and sub-
epidermal blisters with minimal inflammation (Woodley et al,
1984). There is also an inflammatory variety of EBA char-
acterized by vesiculobullous lesions on inflamed skin. The
mice that received immune IgG clearly exhibited skin fra-
gility and nail loss, features of a mechanobullous disease.
Nevertheless, there was some mild inflammation with the
presence of a few neutrophils in the dermis.
In the EBA murine model, the administered immune IgG
fixed murine complement at the DEJ, which is a feature of
sera from both classical EBA and inflammatory EBA (Mo-
oney and Gammon, 1990). Interestingly, EBA antibodies are
more potent activators of complement than are antibodies
in the sera of patients with bullous pemphigoid, a prototypic
inflammatory autoimmune bullous disease (Mooney et al,
1992). The presence of complement-activating IgG autoan-
tibodies does not correlate with the inflammatory or non-
inflammatory EBA clinical phenotypes (Gandi et al, 2000).
In summary, this study provides the first evidence that
antibodies directed against the NC1 domain of human type
VII collagen are pathogenic when passively transferred into
hairless immunocompetent mice. This experimental mouse
model should be useful for dissecting the molecular and
immunological mechanisms of subepidermal blister forma-
tion in EBA and for developing more effective therapy for
EBA.
Materials and Methods
Mice SKH1 mice were obtained from Jackson Laboratories (Bar
Harbor, Maine) and hosted at the University of Southern California
Facility. These are hairless mice with an intact immune system.
The animals were injected with purified rabbit anti-NC1 IgG or
non-immune rabbit control IgG between the ages of 6 and 12 wk.
All animal studies were conducted using protocols approved
by the University of Southern California Institutional Animal Use
Committee.
Generation of rabbit anti-type VII collagen antibody The NC1
was generated in human 293 cells by stable transfection with
a pRC/CMV expression vector, and the recombinant NC1 was
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purified to homogeneity from conditioned media, as previously
described (Chen et al, 1997). New Zealand white rabbits were im-
munized with 10 mg of the recombinant protein injected intrad-
ermally at time 0, 2 wk later, and then with 5 mg every 4 wk. Retro-
occular venous blood was sampled from the animals and tested by
IIF against normal human skin substrate as described (Gammon
et al, 1984, 1985, 1990). Sera from multiple bleedings of the animal
were pooled, and the IgG fractions were purified using protein G
Sepharose Fast Flow chromatography following the manufacture’s
recommendation (Amersham Biosciences, Uppsala, Sweden). IgG
fractions were dialyzed against phosphate-buffered saline (PBS),
concentrated by Centricon Plus-20 ultrafiltration (Amicon, Lexin-
ton, Massachusetts) to 100 mg per mL, filtered sterilized, and
stored at 201C. We then retested it by IIF (antibody dilutions
ranged from 1:500 to 1:200,000) on salt-split skin substrate, west-
ern blot analyses, and ELISA as described (Gammon et al, 1984,
1990; Woodley, 1990; Chen et al, 1997). Identical procedures were
performed using IgG fractions purified from non-immune normal
rabbit serum.
Administration of anti-NC1 IgG to experimental animals SKHl
mice were injected intradermally with rabbit anti-NC1 (n¼ 15) or
rabbit control IgG (n¼ 5) once every day for up to 10 d and ob-
served every day. IgG doses ranged from 0.3 to 1 mg per g body
weight. The animals were photographed at each observation. Skin
erythema, blisters, and erosions were recorded. Mice that devel-
oped blisters had skin biopsies from the blisters and non-blistered
normal-appearing skin within 0.5 cm of a blister. Histological sec-
tions of lesional and perilesional skin were fixed in 10% buffered
formalin and stained with hematoxylin and eosin. Both lesional and
non-lesional tissues were subjected to DIF staining as previously
described. Monospecific fluorescein isothiocyanate (FITC)-con
jugated sera were obtained commercially: goat anti-rabbit IgG
(Sigma, St Louis, Missouri), monospecific goat anti-mouse C3
(Cappel Laboratories, Durham, North Carolina), and FITC-conju-
gated goat anti-mouse neutrophils (Cedarlane, Ontario, Canada).
The Cedarlane monoclonal antibody to murine neutrophils is com-
mercially available and has been used in other murine studies (Hi-
rsch and Gordon, 1983). Nevertheless, although Cedarlane tested
a number of murine strains with this antibody, we could not find in
the literature a reference in which SKH1 mice were specifically
tested. Therefore, in order to be sure that the antibody specifically
stained neutrophils in SKH1 mice, we made thick blood smears
from retro-orbital blood samples of two SKH1 mice and labeled the
smears with the antibody diluted 1:50 in PBS. The Cederlane an-
tibody labeled neutrophils in the smear (data not shown). Photo-
graphs of immunolabeled tissues were obtained with a Zeiss
Axioplan fluorescence microscope equipped with a Zeiss Axiocam
MRM digital camera system (Carl Zeiss, Thornwood, New York).
Sera were obtained from mice at the time of biopsy and ex-
amined for anti-type VII collagen antibodies in the murine serum by
IIF, western blot analysis, and ELISA, as described above and
previously published (Gammon et al, 1984, 1990; Woodley, 1990;
Chen et al, 1997). Animals given rabbit control IgG were studied in
an identical fashion.
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